Ovarian cancer is the 6th most common malignant neoplasm among women worldwide, accounting for 4.3% of all female malignancies (Parkin et al, 1993). Despite advances in surgical and chemotherapeutic ...

Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer. This is an ASCO Meeting Abstract from the ...

A recent article posted to the medRxiv* preprint server discussed the role of complement factor H-related protein 5 (CFHR5) in venous thromboembolism (VTE) patients and hospitalized coronavirus ...

Last year, four independent research groups reported a linkage between polymorphisms in the complement factor H (CFH) gene to age-related macular degeneration (AMD), the most common cause of blindness ...

Among the most significant genetic risk factors for age-related macular degeneration is the Y402H variant of complement factor H, which, along with its splice isoform FHL-1, impairs binding to the ...

Previous studies have linked variants of complement factor H (CFH) and its alternative splicing isoform, FHL-1, with increased complement activation and risk of age-related macular degeneration (AMD).

Panel A shows anti-CFH and anti–phospholipase A2 receptor (PLA2R) antibody concentrations in the patient’s serum at different time points. Anti-CFH concentrations increased over time, whereas ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), ...

Factor H is a soluble complementary glycoprotein present in the blood plasma that serves the primary function of controlling the alternative pathway in blood and maintaining homeostasis. In vitro ...